Genmab — November 2020

[Solsen]

I think if Tapezza, Kesimpta, Darzalex still performing excellent. Amivantamab and TF is on its way to approval we reach a milestone with 3.000 DKK in 2021.

[Sukkeralf]

I agree.................and if a BsAb like PD-L1/4-1BB with the magnitude of 10 billion dollars or higher starts to show off then its hard to guess were we are going

[Sukkeralf]

early days still but valuation comes also early these days

[StockBull]

https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/88181_genmab_rykker.JPG Tror vi skal op og ligge og swinge mellem 2350 til 2650 kommende måneder. Har indikeret en mindre stejl kurve. Har selvfølgelig ikke ikke noget imod Genmab forbliver i den stejle kurve

[Helge_LarsenPI-redaktør]

Genmab/CEO: Darzalex suppleres af flere nye trækheste i 2021
https://www.proinvestor.com/investornyt/669340/genmab-ceo-darzalex-suppleres-af-flere-nye-traekheste-i-2021

[Solsen]

Du var sekundet hurtigere Helge. Bid mærke i, at JW forventer pæne indtægter fra Amivantamab i 2021.

[E_L]

did he not also compare Epcoritamab
to Dara in an interview or am i wrong now?

[Solsen]

Yes we forgot Epco Judith did tell that they will persude all b-cell indications.

[Solsen]

As I recall

[E_L]

and dont forget Dara , many abstracts at ASH and

[E_L]

Janssen Seeks Expanded Use of DARZALEX▼ (daratumumab) Subcutaneous Formulation for the Treatment of Patients with Light Chain (AL) Amyloidosis https://www.businesswire.com/news/home/20201105005525/en/Janssen-Seeks-Expanded-Use-of-DARZALEX▼-daratumumab-Subcutaneous-Formulation-for-the-Treatment-of-Patients-with-Light-Chain-AL-Amyloidosis

[Solsen]

Stockbull på dit chart er tallene i højre side ikke synlige. De ville være interessante - tak

[E_L]

and Genmab also announcing the EMA s
ubmission https://ir.genmab.com/news-releases/news-release-details/genmab-announces-janssen-has-submitted-type-ii-variation

[E_L]

triggers a USD 5 million milestone payment to Genmab.

[E_L]

nobody even bothers mentioning that anymore lol

[Helge_LarsenPI-redaktør]

Genmab-partner søger om tillægsgodkendelse for Darzalex i Europa - NY
https://www.proinvestor.com/investornyt/669343/genmab-partner-soger-om-tillaegsgodkendelse-for-darzalex-i-europa-ny

[Helge_LarsenPI-redaktør]

Jeg minder lige om denne analyse:
https://www.proinvestor.com/boards/86703/Teknisk-analyse-af-Genmab

[Bulder]

Har vi hørt noget om størrelsen af markedet for den særlige type af nsclc, som ami retter sig imod?

[Sukkeralf]

Site Maintenance

(www.jnj.com)

[Sukkeralf]

About Non-Small Cell Lung Cancer (NSCLC)
In the U.S., lung cancer is the second most common cancer in both men and women, after skin cancer; NSCLC makes up 80-85 percent of all lung cancers.[8],[9] The main subtypes of NSCLC are adenoca rcinoma, squamous cell carcinoma, and large cell carcinoma.10 The most common driver mutation for NSCLC is the EGFR genetic alteration, which is a receptor tyrosine kinase that helps cells grow and divide.[10]